{"product_id":"biolegend-329906","title":"Biolegend, 329906, PE anti-human CD279 (PD-1) Antibody, 100tests","description":"\u003cp\u003eProgrammed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.\u003cbr\u003e\n100tests\u003cbr\u003e\nVerified Reactivity: Human\u003cbr\u003e\nReported Reactivity: African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Mouse\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.\u003cbr\u003e\nConcentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)\u003cbr\u003e\nStorage \u0026amp; Handling: The CD279 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested SB - Reported in the literature, not verified in house\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.\u003cbr\u003e\nExcitation Laser: Blue Laser (488 nm)Green Laser (532 nm)\/Yellow-Green Laser (561 nm)\u003cbr\u003e\nApplication Notes: Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF™ purified antibody (Endotoxin \u0026lt;0.1 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin \u0026lt;0.01 EU\/µg).\u003cbr\u003e\nAdditional Product Notes: Iterative Bleaching Extended multi-pleXity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA) Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA) Velu V, et al. 2007. J. Virol. 81:5819. (FA) Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA) Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity) Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC) Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG) Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed\u003cbr\u003e\nProduct Citations: Chen L, et al. 2023. Immunology. 169:204. PubMed Mohammad TAM, et al. 2023. Int J Rheum Dis. 26:740. PubMed Wu X, et al. 2023. iScience. 26:106559. PubMed Pedersen JM, et al. 2023. Arthritis Res Ther. 25:97. PubMed Shaw BI, et al. 2021. J Immunol. 206:1668. PubMed Li M, et al. 2021. J Clin Invest. 131:. PubMed Tocheva AS, et al. 2020. Curr Protoc Immunol. 130:e103. PubMed Asashima H, et al. 2022. J Clin Invest. 132: . PubMed Wei H, et al. 2022. Front Immunol. 13:1060695. PubMed Asashima H, et al. 2023. Cell Rep. 42:111895. PubMed Wu L, et al. 2023. Cell Rep Med. 4:100917. PubMed Saber MM, et al. 2023. J Immunol Res. 2023:4556586. PubMed Fujita T, et al. 2014. J Immunol. 193:5576. PubMed Chang W, et al. 2008. J Immunol. 181:6707. PubMed Wang F, et al. 2018. Oncogenesis. 7:41. PubMed Jung MY, et al. 2022. Neurooncol Adv. 4:vdac017. PubMed Wang W, et al. 2022. World J Gastrointest Oncol. 14:1124. PubMed Rha MS, et al. 2021. Immunity. 54:44. PubMed Li H, et al. 2016. J Immunol. 196: 4064 - 4074. PubMed Diao B, et al. 2020. Front Immunol. 1.032638889. PubMed Huang L, et al. 2018. Mol Med Rep. 18:77. PubMed Kim CJ, et al. 2018. Immunity. 49:1034. PubMed Swadling L, et al. 2020. Cell Rep. 30:687. PubMed Zhou R, et al. 2020. Immunity. S1074-7613(20)30333-2.. PubMed Rosskopf S, et al. 2016. Sci Rep. 6:31580. PubMed Karlsson H, et al. 2015. PLoS One. 10: 0144787. PubMed Lucas C, et al. 2020. Nature. 584:463. PubMed Chen M, et al. 2021. Cancers (Basel). 13:. PubMed Gao Y, et al. 2021. Oncogenesis. 10:62. PubMed Minns D, et al. 2021. Front Immunol. 12:633486. PubMed Findlay EG, et al. 2019. Oncoimmunology. 8:1608106. PubMed Zhu C, et al. 2012. J Clin Endocrinol Metab. 97:943. PubMed Nduom E, et al. 2016. Neuro Oncology. 18: 195 - 205. PubMed Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed Ma X et al. 2019. Cell Metab. 30(1):143-156 . PubMed Edwards CJ, et al. 2021. Br J Cancer. . PubMed Jutz S, et al. 2016. J Immunol Methods. 430:10-20. PubMed Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed Pauthner M et al. 2017. Immunity. 46(6):1073-1088 . PubMed Suzuki M, et al. 2012. J Immunol. 189:2118. PubMed Bonifacius A, et al. 2021. Immunity. 54(2):340-354.e6. PubMed Wang Y, et al. 2021. Front Immunol. 12:654463. PubMed Raghuraman S, et al. 2012. J Infect Dis. 205:763. PubMed Wu L, et al. 2018. Oncol Lett. 15:9507. PubMed Alishah K, et al. 2021. J Transl Med. 19:482. PubMed Smith CM, et al. 2021. Biochem J. 478:3331. PubMed Buggert M, et al. 2020. Cell. 183(7):1946-1961.e15. PubMed Shen C, et al. 2021. Front Immunol. 12:680055. PubMed Song TZ, et al. 2021. Front Endocrinol (Lausanne). 12:745984. PubMed Chen W, et al. 2021. MAbs. 13:1914359. PubMed Vikkurthi R, et al. 2022. Nat Microbiol. 7:974. PubMed OConnor RA, et al. 2021. OncoImmunology. 10(1):1940675. PubMed Colineau L, et al. 2015. PLoS One. 10: e0140978. PubMed Wang C, et al. 2020. Oncologist. 25:382. PubMed Chen Y, et al. 2022. Bioact Mater. 9:251. PubMed Huang RS, et al. 2021. Curr Protoc. 1:e246. PubMed Krishnan S, et al. 2021. Clin Exp Immunol. 203:458. PubMed Xu H, et al. 2013. J Leukoc Biol. 93:943. PubMed Li N, et al. 2020. Oncoimmunology. 9:1824643. PubMed Kamiya T, et al. 2018. Blood Adv. 2:517. PubMed Good Z, et al. 2019. Nat Biotechnol. 37:259. PubMed Ling X, et al. 2022. STAR Protoc. 3:101321. PubMed Capuano C, et al. 2018. Front Immunol. 9:1031. PubMed Pombo C, et al. 2015. J Infect Dis. 12: 1376-1386. PubMed Shuwa HA, et al. 2021. Med. 2(6):720-735.e4. PubMed Radziewicz H, et al. 2010. J Immunol. 184:2410. PubMed Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed Saber MM, et al. 2022. Antibodies (Basel). 11:. PubMed Toor SM, et al. 2021. Vaccines (Basel). 9:. PubMed Xu Y, et al. 2013. J Virol. 87:3760. PubMed Richter M, et al. 2016. Mol Ther Methods Clin Dev. 5:16013. PubMed Matsuyama H, et al. 2019. Sci Rep. 9:13181. PubMed Eriksen LL, et al. 2021. PLoS One. 16:e0255574. PubMed Zheng L, et al. 2020. Clin Cancer Res. 26:3694. PubMed Beyer M, et al. 2016. Nat Immunol. 17:593-603. PubMed Wang B, et al. 2018. Mol Ther Nucleic Acids. 0.548611111. PubMed Ukita M, et al. 2022. JCI Insight. 7:. PubMed Wadley AJ, et al. 2020. Brain Behav Immun Health. 3:100049. PubMed Vojnov L, et al. 2010. J Virol. 84:753. PubMed Shen C, et al. 2021. BMC Med. 19:283. PubMed Zhang C, et al. 2020. Front Oncol. 0.944444444. PubMed Schumann K, et al. 2015. Proc Natl Acad Sci U S A. 112: 10437-10442. PubMed Li B, et al. 2019. Oncogenesis. 8:17. PubMed Cortés–Rubio CN, et al. 2019. Clin Epigenetics. 11:134. PubMed Gamradt S, et al. 2021. iScience. 24:103312. PubMed\u003cbr\u003e\nRRID: AB_940481 (BioLegend Cat. No. 329905) AB_940483 (BioLegend Cat. No. 329906)\u003cbr\u003e\nStructure: Immunoglobulin superfamily\u003cbr\u003e\nDistribution: Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells\u003cbr\u003e\nLigand\/Receptor: B7-H1 (also known as PD-L1) and B7-DC (PD-L2)\u003cbr\u003e\nCell Type: B cells, Lymphocytes, T cells, Thymocytes, Tregs\u003cbr\u003e\nBiology Area: Cancer Biomarkers, Immunology, Inhibitory Molecules\u003cbr\u003e\nMolecular Family: CD Molecules, Immune Checkpoint Receptors\u003cbr\u003e\nGene ID: 5133\u003cbr\u003e\nUniProt: View information about CD279 on UniProt.org\u003cbr\u003e\nClone: EH12.2H7\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: PD-1, PDCD1\u003cbr\u003e\nIsotype: Mouse IgG1, κ\u003cbr\u003e\nQ: What type of PE do you use in your conjugates?\u003cbr\u003e\nA: We use R-PE in our conjugates.\u003cbr\u003e\nQ: If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?\u003cbr\u003e\nA: It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.\u003cbr\u003e\nQ: Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?\u003cbr\u003e\nA: Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF\/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.\u003cbr\u003e\nQ: Are other fluorophores compatible with IBEX?\u003cbr\u003e\nA: Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.\u003cbr\u003e\nQ: The same antibody works in one tissue type but not another. What is happening?\u003cbr\u003e\nA: Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.\u003cbr\u003e\nQ: How can I be sure the staining I’m seeing in my tissue is real?\u003cbr\u003e\nA: In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46863072886953,"sku":"329906","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/biolegend-329906","provider":"Iright","version":"1.0","type":"link"}